Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 2

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 2
---
 “Liquidation Resolution”), and (iv) in the event that the Arrangement Resolution is not approved or
the Arrangement is otherwise terminated, an ordinary resolution pursuant to Section 325 of the QBCA to approve the appointment of KPMG LLP (“KPMG”) or, in the alternative, another liquidator of nationally recognized
experience, as the liquidator of the Company (the “Liquidator”) with authorization for the board of directors of the Company (the “Board”) to set the remuneration of the liquidator (the “Liquidator Resolution”). Pursuant to

the Agreement, the Purchaser will, among other things, acquire all of the issued and outstanding Common Shares, and Shareholders will receive (a) a cash payment per Common Share (the
“Cash Amount”), which is currently estimated to be approximately US$1.82 per Common Share and will be finally determined based upon the Company’s cash balance immediately prior to the date that the Arrangement is completed
(the “Effective Date”) after deducting certain transaction costs, the aggregate amount of outstanding liabilities, and a transaction fee to the Purchaser, and (b) one contingent value right (“CVR”) for each
Common Share (the “CVRConsideration,” and together with the Cash Amount, the “Consideration”) that will entitle the holder to receive, following the Effective Date, contingent cash payments, described
in, and subject to and in accordance with the terms and conditions of, the Contingent Value Rights Agreement (the “CVR Agreement”), all as more particularly described in the Circular and Proxy Statement.

In addition, pursuant to the Arrangement, each stock option (the “Options”) and each restricted share unit of the Company
(the “RSUs,” and together with the Options, the “Incentive Securities”) outstanding as of 12:01 a.m. (Montreal time) (the “Effective Time”) on the Effective Date (whether vested or unvested)
shall be deemed to be unconditionally vested, and in the case of Options, exercisable, and, without any further action by or on behalf of the holder, shall be deemed to be assigned and surrendered by such holder to the Company in exchange for
(A) in respect of each Option for which the Cash Amount exceeds the applicable exercise price in respect of such Option, (i) an amount in cash from the Company equal to the Cash Amount less the applicable exercise price in respect of such
Option, and (ii) one CV